Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Adaptive Phase 2a/2b, Randomized, Double-Blind, Parallel-Group Study to Investigate the Safety and Efficacy of LY3541860 Compared to Placebo in Slowing the Occurrence of New T1 Gadolinium-Enhancing Lesions in Adult Participants With Relapsing Multiple Sclerosis

NCT06220669 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT06220669
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06220669 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Adaptive Phase 2a/2b, Randomized, Double-Blind, Parallel-Group Study to Investigate the Safety and Efficacy of LY3541860 Compared to Placebo in Slowing the Occurrence of New T1 Gadolinium-Enhancing Lesions in Adult Participants With Relapsing Multiple Sclerosis
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Terminated
Start date
March 19, 2024
Completion date
July 13, 2026
Enrollment
63 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis